Drug intelligence / Profile preview

SG3199

Development stage
Preclinical
Lead developer
ADC Therapeutics
Modality
Small Molecules
Administration
Intravenous
01

Overview

SG3199 is a **synthetic pyrrolobenzodiazepine (PBD) dimer** engineered as a DNA minor groove cross-linking agent with **potent cytotoxicity** against a broad range of human solid tumor and hematological cancer cell lines. It acts by forming highly cytotoxic DNA interstrand cross-links that are non-distorting and evade normal DNA repair mechanisms. SG3199 is primarily used as the **released warhead component** of antibody-drug conjugate (ADC) payloads such as tesirine, which is incorporated into several experimental ADCs for targeted cancer therapy. The compound demonstrates high plasma protein binding across species (>90%), rapid cellular uptake, and a very short half-life upon intravenous administration, which helps minimize systemic toxicity. Its effectiveness is enhanced in tumor cells with defects in DNA repair mechanisms, and it is only moderately susceptible to common drug resistance mechanisms[1][5][10][13][16][18].

02

Targets

PuGATCPy (Double-stranded DNA minor groove at 5′-PuGATCPy-3′ guanine-containing sequences)

Beyond the preview

Go deeper on SG3199.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SG3199.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call